https://jamanetwork.com/journals/jama/article-abstract/2817337
Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval
This study aims to determine whether cancer drugs granted accelerated approval from the US Food and Drug Administration ultimately demonstrate clinical benefit and to evaluate the basis of conversion to regular approval.
jamanetwork.com
Importance The US Food and Drug Administration’s (FDA) accelerated approval pathway allows approval of investigational drugs treating unmet medical needs based on changes to surrogate measures considered “reasonably likely” to predict clinical benefit. Postapproval clinical trials are then required to confirm whether these drugs offer clinical benefit.
Objective To determine whether cancer drugs granted accelerated approval ultimately demonstrate clinical benefit and to evaluate the basis of conversion to regular approval.
Design, Setting, and Participants In this cohort study, publicly available FDA data were used to identify cancer drugs granted accelerated approval from 2013 to 2023.
Main Outcomes and Measures Demonstrated improvement in quality of life or overall survival in accelerated approvals with more than 5 years of follow-up, as well as confirmatory trial end points and time to conversion for drug-indication pairs converted to regular approval.
Results A total of 129 cancer drug–indication pairs were granted accelerated approval from 2013 to 2023. Among 46 indications with more than 5 years of follow-up (approved 2013-2017), approximately two-thirds (29, 63%) were converted to regular approval, 10 (22%) were withdrawn, and 7 (15%) remained ongoing after a median of 6.3 years. Fewer than half (20/46, 43%) demonstrated a clinical benefit in confirmatory trials. Time to withdrawal decreased from 9.9 years to 3.6 years, and time to regular approval increased from 1.6 years to 3.6 years. Among 48 drug-indication pairs converted to regular approval, 19 (40%) were converted based on overall survival, 21 (44%) on progression-free survival, 5 (10%) on response rate plus duration of response, 2 (4%) on response rate, and 1 (2%) despite a negative confirmatory trial. Comparing accelerated and regular approval indications, 18 of 48 (38%) were unchanged, while 30 of 48 (63%) had different indications (eg, earlier line of therapy).
Conclusions and Relevance Most cancer drugs granted accelerated approval did not demonstrate benefit in overall survival or quality of life within 5 years of accelerated approval. Patients should be clearly informed about the cancer drugs that use the accelerated approval pathway and do not end up showing benefits in patient-centered clinical outcomes.
'Field Notes > Core Notes : 뉴스' 카테고리의 다른 글
'K제약바이오 안방된 미국'…GC녹십자·휴젤의 7월 빅마켓 데뷔전 (0) | 2024.07.09 |
---|---|
'케이크는 4만원짜리 먹고 화장품은 다이소'…독특한 MZ 소비행태 (0) | 2024.06.22 |
Third Rock, Novo Holdings-backed Clasp Tx hooks $150M series A for next-gen cancer treatments (0) | 2024.06.20 |
SK이노베이션·E&S 합병… 100조 에너지 기업 나온다 (0) | 2024.06.20 |
韓·日·유럽, 37조 바이오 CDMO 쟁탈전 (0) | 2024.06.10 |